Trial Profile
The effects of subcutaneous insulin detemir on glucose flux, pharmacokinetics and brain function in type one diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jun 2016
Price :
$35
*
At a glance
- Drugs Insulin detemir (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- 28 Apr 2015 Accrual to date is 173% as reported by United Kingdom Clinical Research Network.
- 02 Nov 2012 Accrual to date is 100% as reported by United Kingdom Clinical Research Network.
- 02 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.